{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:19Z","timestamp":1790753779854,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:00:00Z","timestamp":1518220800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The immune response against the infection is impaired in patients with chronic hepatitis B, and although <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> can effectively be suppressed by nucleos(t)ide analogues (<jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content>), durable immune control is only established in a minority of patients. This especially applies in <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg\u2010negative patients who usually must receive lifelong <jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content> treatment. Calculated withdrawal of <jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content> leads to a relapse of <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> in most patients. There is evidence that this sudden exposure of viral antigens can trigger immune control in some patients which may result in <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg loss or a form of immune control, then sustained low <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> levels and normal alanine aminotransferase (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>). In the first prospective randomized trial investigating tenofovir treatment cessation in <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg\u2010negative patients, most patients did not need retreatment after <jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content> cessation, although all patients showed a transient relapse in <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg loss was identified in almost 20% nearly 3\u00a0years after stopping <jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content>. Further confirmation of these findings is needed in larger randomized trials and patients who are most likely to benefit from finite therapy must be identified to individualize <jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content> stopping strategies. However, these results suggest that in patients without risk factors such as cirrhosis or other severe conditions, <jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content> treatment may be stopped, as long as adequate safety rules for retreatment are followed.<\/jats:p>","DOI":"10.1111\/liv.13654","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T12:00:22Z","timestamp":1518264022000},"page":"90-96","source":"Crossref","is-referenced-by-count":37,"title":["Stopping long\u2010term treatment with nucleos(t)ide analogues is a favourable option for selected patients with <scp>HB<\/scp>eAg\u2010negative chronic hepatitis B"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0672","authenticated-orcid":false,"given":"Florian","family":"van B\u00f6mmel","sequence":"first","affiliation":[{"name":"Section of Hepatology Clinic for Gastroenterology and Rheumatology University Hospital Leipzig  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[{"name":"Section of Hepatology Clinic for Gastroenterology and Rheumatology University Hospital Leipzig  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030239"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.1.68-76.2003"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2205"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02844-06"},{"key":"e_1_2_11_9_1","first-page":"313A","article-title":"Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8\u00a0year results from two phase 3 trials","volume":"60","author":"Marcellin P","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_11_10_1","first-page":"231A","article-title":"Sustained biochemical and virological remission after discontinuation of 4 to 5\u00a0years of adefovir dipivoxil (ADV) treatment in HBeAg\u2010negative chronic hepatitis B [abstract]","volume":"44","author":"Hadziyannis SJ","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.039"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.026"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw412"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003208"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00556.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2008.00378.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.04.006"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.200"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01178.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365520903394550"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.02.014"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06492.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3350\/kjhep.2011.17.4.261"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1921"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31825ceed9"},{"key":"e_1_2_11_26_1","first-page":"285","article-title":"A prospective clinical study in hepatitis B e antigen\u2013negative chronic hepatitis B patients with stringent cessation criteria for adefovir","volume":"157","author":"Ha M","year":"2012","journal-title":"Adv Virol"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i43.6277"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-458"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2013.19.3.300"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26549"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04738.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23421"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12200"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-439"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12908"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12605"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0047"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.029"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000170"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307237"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3144"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix025"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.012"},{"key":"e_1_2_11_44_1","first-page":"492A","article-title":"DARING\u2010B: discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non\u2010cirrhotic HBeAg\u2010negative chronic hepatitis B (CHBe\u2010) patients: final results of a prospective Greek study","volume":"66","author":"Papatheodoridis GV","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28438"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13150"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12488"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2007.00094.x"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12269"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12108"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.029"},{"key":"e_1_2_11_52_1","article-title":"Nucleos(t)ide analogue interruption: alternative approach to intrahepatic set point for spontaneous control of HBV replication?","author":"Yu Y","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.028"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313811"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12726"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T02:53:24Z","timestamp":1694487204000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":54,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/liv.13654"],"URL":"https:\/\/doi.org\/10.1111\/liv.13654","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}